ReviewMedicina oral, patologia oral y cirugia bucal2020
Review and update on drugs related to the development of osteonecrosis of the jaw.
Review in Medicina oral, patologia oral y cirugia bucal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention.International journal of nanomedicine · 2026Pooled it
- Leukocyte and platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: A systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2023Pooled it
- Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross‑sectional study.BMC oral health · 2026Article
- Possible Contribution of Oral Microbiota in the Osteonecrosis of the Jaw Induced by Zoledronate or Denosumab: A Preliminary Study.Biomedicines · 2026Article
- Effect of nasogastric tube feeding on oral wound healing and oral health-related quality of life (OHRQoL) after surgery for medication-related osteonecrosis of the jaw (MRONJ).Head & face medicine · 2025Article
- Drug-related jaw osteonecrosis: a 6-year retrospective study from two centers in Argentina.Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025Article
- Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review.Cureus · 2025Review
- Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review.Cancers · 2025Review
- Development of a Medication-Related Osteonecrosis of the Jaw Prediction Model Using the FDA Adverse Event Reporting System Database and Machine Learning.Pharmaceuticals (Basel, Switzerland) · 2025Article
- A Novel Formulation Based on Resveratrol and Water Extracts fromFoods (Basel, Switzerland) · 2025Article
- A retrospective, cross-sectional analysis of the dental status and needs of patients taking vascular endothelial growth factor (VEGF) antagonists.Clinical oral investigations · 2025Article
- Alveolar socket surface area as a local risk factor for MRONJ development in oncologic patients on polypharmacy.Clinical oral investigations · 2025Article
- Autologous platelet concentrates as adjuvant in the surgical management of medication-related osteonecrosis of the jaw.Periodontology 2000 · 2025Review
- Combination of Different Laser Wavelengths as a Treatment Strategy for Maxillary Osteonecrosis: A Case Report.Journal of lasers in medical sciences · 2025Article
- Evaluating the Anti-Osteoporotic Potential of Mediterranean Medicinal Plants: A Review of Current Evidence.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Knowledge and attitudes of undergraduate dental students at the University of Barcelona regarding antiresorptive and antiangiogenic medications: A cross-sectional study.Journal of clinical and experimental dentistry · 2024Article
- Extracellular Vesicles from Human Adipose Tissue-Derived Mesenchymal Stem Cells Suppress RANKL-Induced Osteoclast Differentiation via miR122-5p.Biochemical genetics · 2024Article
- A Systematic Review of Laser Photobiomodulation Dosimetry and Treatment Protocols in the Management of Medications-Related Osteonecrosis of the Jaws: A Rationalised Consensus for Future Randomised Controlled Clinical Trials.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Exploring the Impact of Novel Anti-Cancer Therapies on Jaw Osteonecrosis and Other Bones: A Comprehensive Review.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of certain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or aflibercept. Very recently, new medications have also been associated with osteonecrosis of the jaw (ONJ). The objectives were to update the list of medications associated with ONJ, to analyze the fundamental aspects of this list and to describe the level of evidence available. MATERIAL AND
methodsA narrative bibliographic review was made, using the PubMed-MedLine, DOAJ and SCIELO databases. Additional information was obtained through the online Medication Information Centre of the Spanish Agency of Medicines and Medical Devices (AEMPS - CIMA), the websites of the US Food & Drugs Administration (Drugs@FDA) and the European Medicines Agency (EMA).
resultsThe latest drugs identified as potential facilitators of this pathology include a number of anti-VEGF based antiangiogenic drugs and anti-TKI and different types of immunomodulators. Neither the level of evidence in this association nor the risk are equal for all these drugs. On the other hand, over the coming years, new drugs will be marketed with similar action mechanisms to those that are recognized as having this adverse effect.
conclusionsNo effective therapy is currently known for the treatment of ONJ. Therefore, in order to prevent new cases of MRONJ, it is essential for all oral healthcare professionals to be fully up-to-date with the etiopathogenic aspects of this pathology and to be aware of those drugs considered to be a risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.